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To determine what alternative pathways may act as mechanisms of bypass resistance to type 1 insulin-like growth
factor receptor (IGF-1R) blockade in rhabdomyosarcoma (RMS), we compared expression of receptor tyrosine
kinase activity in a number of IGF-1R antibody-resistant and -sensitive RMS cell lines. We found that platelet-
derived growth factor receptor β (PDGFR-β) activity was upregulated in three xenograft-derived IGF-1R antibody-
resistant cell lines that arose from a highly sensitive fusion-positive RMS cell line (Rh41). Furthermore, we
identified four additional fusion-negative RMS cell lines that similarly upregulated PDGFR-β activity when selected
for IGF-1R antibody resistance in vitro. In the seven cell lines described, we observed enhanced growth inhibition
when cells were treated with dual IGF-1R and PDGFR-β inhibition in vitro. In vivo studies have confirmed the
enhanced effect of targeting IGF-1R and PDGFR-β in several mouse xenograft models of fusion-negative RMS.
These findings suggest that PDGFR-β acts as a bypass resistance pathway to IGF-1R inhibition in a subset of RMS.
Therapy co-targeting these receptors may be a promising new strategy in RMS care.
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Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma of
childhood. The annual incidence in the United States is four to seven
cases per million children under 15 years, which represent 250 new
cases per year [1]. Two major histologic subtypes exist: embryonal or
fusion negative and alveolar or fusion positive, the latter of which carries
a particularly poor prognosis. Patients with metastatic and recurrent
disease are essentially incurable with a 5-year overall survival of less than
20%, and outcomes have only minimally improved over the past several
decades [2]. Thus, new therapies for RMS are critically needed.
The insulin-like growth factor (IGF) system plays an important
role in the biology of many cancers. Overexpression of both the type 1
IGF receptor (IGF-1R) and its ligands has been observed in multiple
malignancies, including pediatric sarcomas, and abnormal activation
of this pathway contributes to sarcoma development and progression
[3–5]. Downstream signaling cascades of IGF-1R further regulate
tumor cell proliferation, survival, and metastasis through the MAPK/
ERK and PI3K/mTOR pathways [6]. In samples from human RMS
tumors, IGF-1R has been found to be highly expressed in about 60%
of tumors [7]. Thus, inhibition of IGF-1R is a potentially important
therapeutic target in RMS.Monoclonal antibodies targeting IGF-1R interfere with ligand
binding and decrease the expression of the receptor on cell surfaces by
internalization and degradation of the receptor [8–11]. A number of
these antibodies have been tested in the clinical setting. Results from
early-phase clinical trials usingmonotherapy with R1507, amonoclonal
antibody against IGF-1R, indicated clinically meaningful responses in
about 10% to 15%of patients with RMS.However, the vastmajority of
these responses were short-lived with a rapid onset of resistance [12].
We previously reported data from mouse xenograft models of RMS,
which revealed a phenomenon similar to that seen in the adult clinical
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IGF-1R, showed a progression-free period of about 9 weeks compared
with 3 weeks in control animals. Evaluation of the tumor samples from
treated mice after regrowth showed persistent downregulation of
IGF-1R but a rebound in AKT phosphorylation. This suggests that the
resistance was not due to loss of activity of the antibody against IGF-1R
but rather the result of a bypass resistance pathway [7].
By investigating the potential molecular bypass mechanisms that
enable this type of acquired resistance, our goal is to shift the focus from
targeting single pathways to targeting larger networks in an effort to
overcome treatment failures. We recently published preclinical work
showing that in both embryonal and alveolar RMS models, blockade of
IGF-1R results in activation of YES, an Src family kinase member, and
that YES activation is associated with resistance to IGF-1R blockade. In
addition, combination treatment blocking both IGF-1R and YES
resulted in enhanced growth inhibition of both embryonal and alveolar
RMS in vitro and in vivo [13]. However, given the heterogeneous nature
of these tumors, it is likely that multiple mechanisms of resistance to
IGF-1R blockade exist. Hence, we sought to identify other specific
molecular mechanisms mediating the bypass of IGF-1R blockade.
Material and Methods
Generation of IGF-1R Antibody-Resistant Cell Lines
Cell Lines. Alveolar (fusion-positive) RMS cell lines Rh30 and
Rh41 and embryonal (fusion-negative) cell line RD have been
previously described [14]. Alveolar (fusion-positive) cell lines Rh5,
JR, and Rh28 and embryonal (fusion-negative) cell lines TTC-442
and TTC-516 were obtained from Dr. Javed Khan (NCI, Bethesda,
MD). Embryonal (fusion-negative) cell line Rh18C was obtained
from Dr. Frederick Barr (NCI, Bethesda, MD). Embryonal
(fusion-negative) cell line Rh36 was obtained from Dr. Maria Tsokos
(Beth Israel Medical Center, Boston, MA).
Compounds. R1507 antibody was obtained from Hoffman-La
Roche Inc. (Nutley, NJ).
In Vitro Resistance. Cells were maintained in RPMI growth
medium (Life Technologies, Grand Island, NY) with 10% FBS,
heat-inactivated (Sigma-Aldrich, St. Louis, MO), 100 U/ml of
penicillin and 100 μg/ml of streptomycin (Life Technologies), and
2mML-glutamine (Life Technologies) at 37°C in an atmosphere of 5%
CO2. For each cell line, two flasks were maintained: one with media
alone (termed parental) and one with media plus R1507 at 100 nM
(termed resistant). Resistant cells weremaintained in R1507media with
the drug replenished with each media change for at least 6 weeks before
experiments commenced.
In Vivo Resistance. Animal studies were performed in accordance
with the guidelines of the National Institutes of Health Animal Care
and Use Committee. Four- to 6-week-old female Fox Chase severe
combined immunodeficiency (SCID)-Beige mice were purchased from
Charles River Laboratories (Wilmington,MA). Twomillion Rh41 cells
were suspended in a solution of Hank’s balanced salt solution and
Geltrex LDEV-free reduced growth factor basement membrane matrix
(Matrigel) (Life Technologies) mixed at a 1:1 ratio and injected
orthotopically into the gastrocnemius muscle in the left hind leg of each
mouse. When tumors were palpable, mice began treatment with
intraperitoneal (IP) R1507 at 6 mg/kg weekly. Tumors regressed and
eventually regrew while mice continuously received R1507 treatments.
When tumors reached 1500 to 2000 mm3, they were harvested under
sterile conditions and aspirated or cut into small sections. Tumoraspirates and sections were incubated in cell culture flasks in complete
RPMI until cell lines were established. Cell lines from individual mice
were kept and named separately. Resistance to R1507 was confirmed
in vitro with exposure to R1507 at 100 nM and in vivo with reinjection
into mice and subsequent treatment with R1507 at 6 mg/kg weekly.
Identification of PDGFR-β Activation
PDGFR-β activation was identified and tested using the following
methods: receptor tyrosine kinase (RTK) array, Western blotting, and
MesoScale analysis.
RTK Array. Cell lines were prepared, lysed, and compared
according to the protocol from the Proteome Profiler Human
Phospho-RTK Array Kit (Bio-Techne, Minneapolis, MN).
Lysate Preparation and Ligand Stimulation for Western Blot and
MesoScale Analysis. Cells were plated in RPMI growth medium
for 24 hours. After 24 hours, medium was removed, and each plate
was treated with ligand stimulation with 25 ng/ml of PDGF-BB
(Bio-Techne) or vehicle in RPMI with glutamine only. Plates were
incubated for 10 minutes at 37°C and then immediately placed on ice for
harvest. Cells were washed twice with ice-cold PBS (Life Technologies)
and then lysed with LDS lysis buffer (Sigma Aldrich) with phosphatase
and protease inhibitors (Life Technologies).
Western Blot Analysis. Protein lysates (30-60 μg/lane), as
determined by BCA protein assay (Life Technologies), were
separated in 4% to 12% SDS-PAGE (Life Technologies) and
transferred to nitrocellulose membranes (Amersham Pharmacia
Biotech, Piscataway, NJ). Membranes were blocked with 5% nonfat
dried milk in TBS (KPL, Gaithersburg, MD)-Tween 20 (Sigma
Aldrich) (20 mm Tris-HCI, pH 7.5; 8 g/l of sodium chloride;
0.1% Tween 20). Blots were incubated with antibodies against
total PDGFR-β and phospho-PDGFR-β (tyr751) (Cell Signaling
Technology, Beverly, MA) at a 1:1000 dilution. Antiactin antibody
from Abcam Inc. (Cambridge, MA) was used as a loading control. Bands
were visualized on camera using West Femto ECL detection reagent
(Life Technologies).
MesoScale Analysis. Protein lysates were quantified by BCA protein
assay (Life Technologies) and added to MesoScale Discovery Multi-spot
4 Spot 96-well plates (Rockville, MD). Samples were analyzed in
triplicate using theMesoScaleDiscovery Sector Imager 2400 plate reader.
In Vitro Proliferation Studies
Cell proliferation kinetics were monitored and recorded with the
IncuCyte System (Essen BioScience, Ann Arbor, MI). Imatinib,
pazopanib, and crenolanib were all obtained from Selleck (Houston,
TX). For all in vitro experimentations, all three compounds were
dosed at 1 μM. R1507 was dosed at 100 nM.
In Vivo Studies
SCID-Beige mice as described above were injected with two
million cells of Rh36 or Rh18C (details of injection are specified in
the in vivo resistance section above). Mice were randomized after
tumors developed but prior to the start of treatment. Treatment with
agents began when tumors were palpable, which was on day 21 for
Rh36 and day 86 for Rh18C. R1507 was given by IP injection at
6 mg/kg weekly. Crenolanib was given by IP injection at 15 mg/kg
daily 5 days per week. Treatments were continuous.
All mice were maintained in a pathogen-free environment and
monitored weekly for tumor growth. Tumors were measured twice per
week with calipers, and mice were weighed weekly to determine drug
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V (mm3) = (D × d2)/6 × 3.14, whereD (mm) is the longest tumor axis
and d (mm) is the shortest tumor axis. Tumors were harvested at
midpoints and at study end point for biology studies.
Statistical Analysis
Activity of PDGFR-β in cell lines was compared between groups using
a nonparametric t test. Statistical significance was defined as P b .05.
Tumor volumes were compared between groups using a nonpara-
metric t test at time points selected to be appropriate according to the
data being presented in each plot. Measurements for mice that had
already reached end pointwere carried forward until all mice in the group
had reached end point or the experiment was terminated. Mice that had
not developed tumor by the time of drug treatments were discarded from
the analysis. Statistical significance was defined as P b .05.
Results
RMS cell lines with acquired resistance to IGF-1R blockade were
analyzed to determine what other pathways might be contributing to
bypass resistance. Upregulation of PDGFR-β activity was identified in
three IGF-1R antibody-resistant cell lines that were generated in vivo
from a previously highly sensitive parental line (Rh41) and in four of
nine additional IGF-1R antibody-resistant cell lines that were generated
in vitro from parental lines with varying IGF-1R antibody sensitivity.
In vitro experiments using dual blockade of IGF-1R and PDGFR-β
resulted in enhanced growth inhibition in cell lines that displayed
upregulated PDGFR-β activity, whereas cell lines that did not
upregulate PDGFR-β activity did not respond to the combination. In
mouse xenograft models of cell lines that showed in vitro sensitivity to
dual blockade of IGF-1R and PDGFR-β, combination therapy also
produced superior inhibition of tumor growth.
PDGFR-β Activation in Xenograft-Derived Cell Lines
Resistant to IGF-1R Blockade
In vitro testing of a parental cell line (Rh41) that was highly sensitive
to IGF-1R blockade and its daughter cell lines (Rh41.R1 (R1),
Rh41.R2 (R2), Rh41.R3 (R3), and Rh41.R4 (R4)) that were derived
from xenografts of Rh41 treated with prolonged IGF-1R inhibition
revealed that R2, R3, and R4 retained resistance to R1507 in culture,
whereas R1 did not (Figure 1, A and B). Comparison of the sensitive
(Rh41 and R1) and resistant lines (R2) by receptor phosphotyrosine
kinase (RTK) array demonstrated that R2 resistant cells expressed
increased phosphorylation of PDGFR-β, whereas the parental Rh41 cell
line and the xenograft-generated nonresistant cell line R1 did not
express any PDGFR-β. In addition, both sensitive (Rh41 and R1) and
resistant (R2) cell lines expressed high levels of phosphorylated IGF-1R,
HGFR, and FGFR-4, a finding that is consistent with published data on
alveolar RMS cell lines [15,16]. In the resistant cells, subsequent
exposure to IGF-1R blockade in vitro further increased phosphorylation
of PDGFR-β, reduced phosphorylation of IGF-1R, and did not
significantly alter phosphorylation of HGFR or FGFR-4 (Figure 1C).
Western blot and MesoScale analyses using PDGF-BB for ligand
stimulation confirmed the findings of the RTK array. ByWestern blot,
resistant cell line R2 displayed an increase in phosphorylated PDGFR-β
with ligand stimulation. In contrast, in nonresistant cell lines Rh41 and
R1, phosphorylated PDGFR-βwas not detected with or without ligand
stimulation (Figure 1D). By MesoScale analysis, R2, R3, and R4
expressed higher levels of phosphorylated PDGFR-β compared with
Rh41 when stimulated with ligand. For all three cell lines, this
difference reached statistical significance (P b .05) (Figure 1, E and F).Upregulation of PDGFR-β Activation in Additional Cell Lines
Under Prolonged IGF-1R Inhibition
To determine whether the upregulation of phospho-PDGFR-β
noted in R2, R3, and R4 was an isolated observation in Rh41-derived
cell lines or if other RMS cell lines would similarly activate PDGFR-β
when they developed resistance to IGF-1R blockade, nine additional
RMS cell lines (four alveolar, five embryonal) were investigated. In vitro
IGF-1R antibody resistance was generated through prolonged R1507
exposure, and the resulting resistant daughter cell lines were screened
against their corresponding parental cell lines to identify expression
differences in PDGFR-β phosphorylation. Four of the nine cell lines
(Rh18C, Rh36, TTC-442, and TTC-516) displayed a statistically
significant increase (P = .005, P = .002, P = .02, and P = .03,
respectively) in phosphorylated PDGFR-β after 8 weeks of exposure
to R1507, suggesting that PDGFR-β activation in this context was not
unique to Rh41 cells. Interestingly, all four of the cell lines identified are
of the embryonal subtype (Figure 2).
Co-Inhibition of IGF-1R and PDGFR-β In Vitro
Target inhibition of PDGFR-β in R2 using both imatinib and
pazopanib demonstrated that both drugs downregulate PDGFR-β
activity. Imatinib reduced levels of activation by approximately 7-fold
(P = .0015), and pazopanib did so by about 25-fold (P = .0012)
(Figure 3A). Of note, a pure PDGFR-β inhibitor does not exist, but
several tyrosine kinase inhibitors that target PDGFR-β are commer-
cially available. Imatinib, pazopanib, and crenolanib were used in
these in vitro experiments, with crenolanib being the most specific
and targeting only PDGFR-β, PDGFR-α, and FLT-3. Based on data
from the RTK array, the resistant cell lines did not highly express
PDGFR-α or FLT-3; thus, inhibitory activity on these kinases was
not expected to significantly affect the cells.
Combination treatment of R2, R3, and R4 with R1507 and the
aforementioned tyrosine kinase inhibitors revealed enhanced growth
inhibition in all three of the cell lines when compared with any single
agent alone. In R2, R1507 plus pazopanib more profoundly inhibited
cell growth than R1507 plus imatinib did (Figure 3B). Interestingly,
this corresponded to the greater degree of PDGFR-β inhibition
observed with pazopanib in this cell line (Figure 3A). In R3 and R4,
combination treatment with R1507 and crenolanib similarly resulted
in enhanced cell growth inhibition when compared with either single
agent alone (Figure 3, C and D).
Additionally, in all four of the embryonal cell lines identified as
upregulating PDGFR-β during development of IGF-1R antibody
resistance (Rh18C, Rh36, TTC-442, and TTC-516), combination
therapy with R1507 and pazopanib resulted in superior growth
inhibition (Figure 3E). Repeating this experiment with crenolanib
recapitulated these results (Figure 3F). In contrast, cell lines that did not
show increased phosphorylation of PDGFR-β with development of
resistance to IGF-1R blockade, such as RD and Rh30, were not
sensitive to this combination (data not shown). These findings suggest
that activation of PDGFR-β is responsible for bypass resistance to
IGF-1R blockade in a selected subset of RMS.Dual Blockade of IGF-1R and PDGFR-β in RMS Xenografts
Based on pilot studies to determine growth kinetics in vivo, Rh36
and Rh18C were selected from cell lines that displayed upregulation
of PDGFR-β in vitro for use in xenograft studies due to their reliable
tumor take and consistent growth pattern. Although consistent, the
growth rate for Rh18C was slow, with a latency of about 80 days and
Figure 1. (A andB) Xenograft-derivedR1507 resistant cell linesR2, R3, andR4maintained resistance toR1507 in vitro, whereas parental Rh41
and R1 remained sensitive. (A) Cells were plated in 96-well plates at a density of 3000 cells per well and placed in the IncuCyte. Cells were
treated with 100 nM R1507 starting at time 0 and redosed every 3 days. Each data point represents an average of 32 wells. (B) Cells were
plated in 96-well plates at a density of 2000 cells per well and placed in the IncuCyte. Cells were treated with one dose of R1507 (100 nM) at
24 hours. Each data point represents an average of 16wells. (C) Phospho-PDGFR-βwas increased in resistant cell line R2 (3), but not in R1 (2),
when compared with parental Rh41 (1) by RTK array. When R2 was treated with R1507, phospho-IGF-1R decreased, as expected, and
phospho-PDGFR-β increased further (4). HGF-R, FGFR-4, and IGF-1R were the most highly phosphorylated receptors across all tested cell
lines. (D) With PDGF-BB ligand stimulation, phospho-PDGFR-βwas detected by Western blot at high levels in R1507 resistant R2 but not in
parental Rh41 or nonresistant R1, confirming the RTK array data. Cells were grown in 10-cm tissue culture plates in complete RPMI for
24 hours. After 24 hours, medium was removed, and each plate was treated with PDGF-BB ligand stimulation with 25 ng/ml of PDGF-BB or
vehicle in RPMI with glutamine only. Plates were incubated for 10 minutes at 37°C and then immediately placed on ice for harvest.Fifty
micrograms of protein was loaded per lane. A172 glioblastoma cells stimulated with ligand were used as positive controls. Blot was probed
with anti-phospho-PDGFR-β. Beta-actin was used as loading control. (E) With PDGF-BB ligand stimulation, phospho-PDGFR-βwas detected
at significantly higher levels in R1507 resistant R2 comparedwith parental Rh41 (P = .001) byMesoScale. Cells were grown and treatedwith
PDGF-BB ligand or vehicle as described above. Whole cell lysates were added to MSD Multi-spot 4 Spot 96-well plates after protein
standardization (25 μg/well). Phosphorylated proteins were detected with MSD Sulfo-Tag detection antibodies. Experiments were done in
triplicate. (F) With PDGF-BB ligand stimulation, phospho-PDGFR-β was detected at significantly higher levels in R1507 resistant R3 and R4
compared with parental Rh41 (P = .022 and P = .035, respectively). Methods were as described in (E).
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schedule for crenolanib administration was daily IP injections 5 days
per week, Rh18Cmice receiving crenolanib were treated with asmany as45 IP injections over a 9-week period, which resulted in substantial
morbidity in some animals. Specifically, repetitive dosing of the agent
resulted in IP adhesions and subsequent bowel obstruction, necessitating
Figure 2. Rh36 (P = .005), Rh18C (P = .002), TTC-442 (P = .02), and TTC-516 (P = .03) displayed significantly increased activation of
PDGFR-β with acquired in vitro resistance to IGF-1R blockade. RD, Rh28, Rh30, Rh5, and JR did not show this effect. Cells were grown
and selected for in vitro resistance to IGF-1R inhibition using continuous IGF-1R antibody (R1507) exposure for 8 weeks to create parental
and resistant pairs. Ligand stimulation with PDGF-BBwas performed as described in Figure 1D. MesoScale methods were as described in
Figure 1E. Protein standardization by BCA was performed within each pair and quantified as follows: Rh36-58 ug, Rh18C-27 ug, TTC-442-65
ug, TTC-516-24 ug, RD-64 ug, Rh28-17 ug, Rh30-64 ug, Rh5-15 ug, JR-5 ug. Experiments were done in triplicate.
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tumors had reached end point. This also occurred in Rh36 mice
receiving the combination but to a lesser degree, as these mice were
treated for a shorter duration and the effect was more pronounced with
longer exposure. Measurements from mice requiring euthanasia prior to
reaching end point were only included in the analysis until the day they
were euthanized and then were removed to avoid artificially depressing
average tumor size in the combination groups.
In both models, combination therapy with R1507 and crenolanib
resulted in greater suppression of tumor growth compared with all other
treatment groups. This was reflected by a slower growth rate of the
tumors in mice treated with the combination (Figure 4, A and B). In
Rh36, the differences in tumor sizes between the group treated with
R1507 and the group treated with the combination reached statistical
significance between day 63 (P = .0499) and day 81 (P = .0241),
which was the end of the experiment (Figure 4, C and D). In mice
bearing Rh18C tumors, statistical significance between tumors sizes was
not reached despite the apparently slower growth rate in the
combination group likely because of the aforementioned toxicity
reducing the number of animals remaining in the combination group.Figure 3.Upper panel: (A) Imatinib (P = .0015) and pazopanib (P = .001
was inhibitedmost completely by pazopanib (P = .0019). Cells were pla
growth, drug treatments of DMSO, imatinib (1 μM), or pazopanib (1 μM
before lysing. Ligand stimulation with PDGF-BB was performed as d
Figure 1E. Experiments were done in triplicate with protein loaded at
(100 nM), imatinib (1 μM), pazopanib (1 μM), imatinib plus R1507, and
receiving a combination of R1507 and pazopanib. Cells were plated in
applied at 24 hours. Retreatment was done every 3 days. Each data po
IGF-1R and PDGFR-β with R1507 and crenolanib resulted in enhanced
plate at a density of 2000 cells per well. At 24 hours, cells were treat
crenolanib. Each data point represents an average of 12 wells.Lower pa
pazopanib (1 μM) (E) or with R1507 (100 nM) and crenolanib (1 μM) (F) r
TTC-516. Cells were plated in a 96-well plate at various densities to opti
and TTC-442 at 2000 cells/well. At 24 hours, treatment was administerIn both Rh36 and Rh18C, mice receiving crenolanib alone experienced
tumor growth at the same rate as the vehicle group, and in Rh18Cmice,
R1507 had no effect as a single agent, suggesting that the advantage of
the combination therapy was synergistic in these models.Discussion
Early-phase clinical trials in RMS have shown encouraging results using
antibodies against IGF-1R. However, the potential of these agents has
been limited because most patients respond for a short time before the
onset of resistance. Our current work focused on identifying and
targeting PDGFR-β in its capacity as an alternative bypass mechanism of
resistance in RMS. Data from our preclinical RMS models suggest that
signaling through PDGFR-β results in bypass of IGF-1R blockade and
contributes to IGF-1R resistance in three cell lines (R2, R3, and R4)
derived in xenografts from a previously sensitive alveolar RMS cell line
(Rh41) as well as in four additional embryonal RMS cell lines (Rh18C,
Rh36, TTC-441, and TTC-516). In these cell lines, an increase in
PDGFR-β activation is observed with prolonged exposure to IGF-1R
blockade and the development of IGF-1R antibody resistance. Both2) inhibited phospho-PDGFR-β activity in R2cells. Phospho-PDGFR-β
ted in a 96-well plate at a density of 3000 cells per well. At 24 hours of
) were applied, and cells were incubated for an additional 24 hours
escribed in Figure 1(D). MesoScale methods were as described in
10 μg/well.(B) IncuCyte plot of R2 cells treated with DMSO, R1507
pazopanib plus R1507. Growth inhibition was most profound in cells
a 96-well plate at a density of 3000 cells per well. Treatments were
int represents an average of 16 wells.Center panel: Dual inhibition of
growth inhibition in R3 (C) and R4 (D). Cells were plated in a 96-well
ed with DMSO, R1507 (100 nM), crenolanib (1 μM), or R1507 plus
nel: Dual inhibition of IGF-1R and PDGFR-βwith R1507 (100 nM) and
esulted in enhanced growth inhibition in Rh18C, Rh36, TTC-442, and
mize growth as follows: Rh18C and TTC-516 at 4000 cells/well, Rh36
ed. Each data point represents an average of 24 wells.
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combination therapy against IGF-1R and PDGFR-β results in enhanced
growth inhibition in the cell lines that upregulate PDGFR-β when
exposed to IGF-1R blockade compared with single-agent therapy alone.These findings collectively suggest that PDGFR-β may be acting as a
bypass resistance pathway in a subset of RMS.
Multiple studies have described mechanisms that aid in the
development of resistance to IGF-1R blockade. We recently reported
A B
C D
Figure 4. Dual inhibition of IGF-1R and PDGFR-β in Rh36 and Rh18C xenografts resulted in slower tumor growth (A and B). In Rh36, differences
in tumor sizes between the R1507 group and the combination group reached statistical significance between day 63 (P = .0499) (C) and day 81
(P = .0241) (D). In Rh18C, statistical significance was not reached likely because of insufficient number of animals. Two million cells were
injectedorthotopically into thegastrocnemiusmuscle of SCID-Beigemice.Micewere allowed todevelop palpable tumors before randomization
into four groups [vehicle, R1507, crenolanib, and combination (R1507 plus crenolanib)]. Weight wasmeasuredweekly to determine tolerability.
Tumors were measured twice weekly. Mice were sacrificed at interim time points for tissue collection and at end point (2 cm).
546 PDGFR-β Activation in IGF-1R Blockade Resistant RMS Heske et al. Translational Oncology Vol. 9, No. 6, 2016the identification of YES/Src family kinase signaling as a bypass resistance
mechanism in preclinical models of RMS [13]. Additional preclinical
studies of RMS have reported that Her2 heterodimers and PDGFRA-α
expression contribute to IGF-1R inhibitor resistance [17,18]. In other
cancer types, overexpression of IGF binding proteins and heat shock 90
protein has been found to promote resistance to these agents [19,20]. This
is the first study to report on upregulation of PDGFR-β expression acting
as a potential bypass pathway in IGF-1R antibody-resistant cell lines.
As we previously reported, an increase in AKT phosphorylation
despite persistent downregulation of IGF-1R in RMS xenograft tumors
treated with an IGF-1R antibody suggested that resistance was the result
of a bypass resistance pathway signaling through AKT [7]. We again
observed this effect in our xenograft samples treated with R1507.
Interestingly, PDGFR-β and IGF-1R both signal through the same two
major pathways, PI3K andMAPK/ERK, and as AKT is part of the PI3K
pathway, PDGFR-β activation may explain the reactivation of AKT in
resistant cells. Moreover, when resistant cells are exposed to continuous
IGF-1R inhibition, PDGFR-β activation is further increased, suggesting
that once PDGFR-β becomes activated as a bypass pathway, cells depend
more heavily on signaling through it for growth.
Other studies have reported that PDGFR-β activity mediates
resistance through the AKT pathway in various cancer types. Juliachs
et al. described that acquired resistance to cisplatin in testicular cancer
develops as a result of overexpression of PDGFR-β; Akhavan et al. found
that derepression of PDGFR-β transcription contributes to resistance toEGFR inhibitors in glioblastoma [21,22]. Clinically, an increase in
PDGFR-β activation may act as a biomarker for predicting resistance to
IGF-1R inhibition in patient tumors. Published data support this idea, as
analysis of human RMS tumors has shown heterogeneous expression of
PDGFR-β in patient samples, with high-expressing tumors portending
worse prognoses (Oncogenomic Database, http://home.ccr.cancer.gov/
oncology/oncogenomics/).
An enhanced inhibitory effect of rational combination therapy
targeted against IGF-1R and other identified bypass pathways has been
reported in the literature [13,20]. Furthermore, targeted therapy against
PDGFR-β in cell types where it has been identified as a resistance
mechanism has restored sensitivity of those cells to the original agent
[21,22]. In our study, both in vitro and in vivo findings demonstrated
an enhanced inhibitory effect of combination therapy against IGF-1R
and PDGFR-β. The ability of these combinations to overcome acquired
resistance to IGF-1R blockade in a number of RMS cell lines and
xenograft tumors suggests that rational combination therapy has the
potential to outpace tumor bypass andmay be a promising combination
for patients with RMS.
One limitation of our study is that the xenograft-derived resistant cell
lines all originated from the same alveolar cell line (Rh41) and thus may
not reflect RMS overall. Hence, the cell line screen was performed to test
whether PDGFR-β activation was an isolated event in Rh41 or more
broadly observed. The four additional embryonal cell lines identified in
the screen further support the fact that PDGFR-β activation occurs not
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resistant RMS. Specifically, this mechanism appears to predominate in
embryonal RMS.
An additional limitation affecting the in vivo experiments was the
toxicity of long-term daily IP crenolanib administration, as described in
the results section. Although other PDGFR inhibitors with less toxic
dosing schedules were considered for these experiments, many have a
large number of targets in addition to PDGFR. To minimize off-target
effects, crenolanib was selected because of its specificity for inhibiting
only PDGFR and FLT-3, which is not expressed in these cells.
However, because of the unexpected toxicity associated with long-term
dosing of crenolanib, a number of animals receiving this agent were lost,
and the statistical power of the Rh18C experiment in particular was
reduced. The toxicity appeared to be related specifically to the IP route
of administration, as mice receiving crenolanibmaintained body weight
and normal activity throughout the experiment.
In summary, we have identified PDGFR-β activation as a potential
bypass pathway contributing to IGF-1R blockade resistance in RMS
and demonstrated that there is enhanced antitumor activity when both
pathways are targeted in this subset of RMS. Although PDGFR-β
activation appears to be an important bypassmechanism in the subset of
RMS cell lines we have tested, we recognize that the development of
resistance is complex and PDGFR-β activation will not be the only
contributing factor. In fact, PDGFR-β activation is certainly one of
many potential mechanisms at play. Hence, the clinical relevance of
these findings may lie in the identification of patients with PDGFR-β
activation in their tumors, who may experience an enhanced benefit
from dual therapy against IGF-1R and PDGFR-β.
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